Breaking News

Partner Therapeutics Acquires Leukine from Sanofi

Purchase includes Lynnwood, WA biologics manufacturing facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boston-based cancer company Partner Therapeutics (PTx) has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi. Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infections. Leukine is used to treat or prevent severe and life-threatening infections and is the only immune modulator approved by the FDA for the treatment of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters